Opioids show modest benefit for acute breathlessness, cannabinoids untested

This systematic review examined the effectiveness and safety of centrally acting drugs—including opioids, benzodiazepines, and cannabinoids—for treating acute breathlessness that requires relief within 20 minutes or less. Researchers analyzed 11 randomized controlled trials involving 334 participants, primarily focusing on opioid treatments. The analysis revealed that only intravenous morphine and subcutaneous morphine showed modest benefits compared to placebo, with mean reductions of 1.8 and 1.1 centimeters respectively on breathlessness scales. Notably, other fast-acting delivery methods—including inhaled opioids, intranasal fentanyl, and oral hydromorphone—showed no significant benefit over placebo, challenging the routine use of these approaches.

The review highlights critical safety concerns that warrant attention. In acute-care settings, serious adverse events were actually more frequent in the morphine treatment arms compared to controls, raising important questions about risk-benefit ratios. Additionally, the research found that benzodiazepines like midazolam showed no clear advantage over placebo or morphine in the limited trials conducted. Significantly, the paper notes that no clinical trials have yet investigated cannabinoids for acute breathlessness relief, despite their inclusion in the systematic review protocol.

The authors recommend a cautious, stepped approach to treating rapid-onset breathlessness: non-pharmacological measures should be attempted first, with fast-acting opioids (specifically subcutaneous or intravenous morphine) considered only as a second-line option when other methods fail. The review emphasizes the urgent need for further research into centrally acting drugs, particularly regarding adverse effects and long-term safety profiles, as current evidence remains limited and methodologically inconsistent across available studies.